echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Jingxin Pharmaceutical Memantine Hydrochloride Sustained Release Capsules Obtained Drug Registration Approval

    Jingxin Pharmaceutical Memantine Hydrochloride Sustained Release Capsules Obtained Drug Registration Approval

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 15, Jingxin Pharmaceutical announced that it had recently received the "Drug Registration Certificate" for the chemical drug "Memantine Hydrochloride Sustained Release Capsules" [Specification 28mg] approved and issued by the State Food and Drug Administration


    Memantine hydrochloride is a low to moderate affinity non-competitive N-formyl-D-aspartate (NMDA) receptor antagonist, suitable for moderate to severe Alzheimer's dementia


    Upon inquiry, as of the announcement date, domestic companies that have been approved to list memantine hydrochloride sustained-release capsules include Chengdu Wandong Biopharmaceutical Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.